Indivior PLC (LSE:INDV) plans to seek shareholder approval next month for a primary listing in the United States, the company said on April 25, 2024, which would add it to a growing list of firms leaving the London stock market. Indivior had, in February, announced its intent to shift its listing by the middle of the year to the U.S., which, it argued, reflected its growth opportunities as its proprietary treatments are U.S.-centred and U.S.-based investors account for nearly 50% of its overall shareholder base.